In the mix: the potential benefits of adding GM-CSF to CpG-B in the local treatment of patients with early-stage melanoma. (1st January 2020)

• Record Type: Journal Article
• Authors: Koster, Bas D.; de Jong, Tamarah D.; van den Hout, Mari F. C. M.; Sluijter, Berbel J. R.; Vuylsteke, Ronald J. C. L. M.; Molenkamp, Barbara G.; Vosslamber, Saskia; van den Tol, M. Petrousjka; van den Eertwegh, Alfons J. M.; de Gruijl, Tanja D.
• Is Part Of: Oncoimmunology. Volume 9:Number 1(2020)
• Publication Date: 2020-01-01
• Subjects: GM-CSF -- CpG -- melanoma -- dendritic cells -- sentinel lymph node; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2019.1708066
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: Whereas TLR9 agonists are recognized as powerful stimulators of antitumor immunity, GM-CSF has had mixed reviews. In previously reported randomized trials we assessed the effects of local immune modulation in early-stage melanoma with CpG-B alone or with GM-CSF. Here we discuss the added value of GM-CSF and show sex-related differences.